Arnd Schwebig

Suggest Changes
Learn More
BACKGROUND Biosimilars of filgrastim are in widespread clinical use in Europe. This phase III study compares biosimilar filgrastim (EP2006), with the US-licensed reference product, Neupogen(®), in(More)
OBJECTIVE Two strengths of a novel ready-to-use liquid preparation of the recombinant human GH (rhGH) Omnitrope were developed to increase the convenience for the patients. DESIGN Omnitrope 3.3(More)
  • 1